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BRIEF COMMUNICATION OPEN
Patient-derived orthotopic xenograft models for cancer of
unknown primary precisely distinguish chemotherapy, and
tumor-targeting S. typhimurium A1-R is superior to first-line
chemotherapy
Kentaro Miyake 1,2,3, Tasuku Kiyuna1,2, Masuyo Miyake1,2,3, Kei Kawaguchi1,2, Sang Nam Yoon1,2, Zhiying Zhang1,2, Kentaro Igarashi1,2,
Sahar Razmjooei1,2, Sintawat Wangsiricharoen1, Takashi Murakami3, Yunfeng Li4, Scott D. Nelson4, Tara A. Russell5, Arun S. Singh6,
Yukihiko Hiroshima3, Masashi Momiyama3, Ryusei Matsuyama3, Takashi Chishima3, Shree Ram Singh 7, Itaru Endo3,
Fritz C. Eilber5 and Robert M. Hoffman1,2
Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy.
CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify
an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness
of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium
A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which
was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective
for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line
chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective
therapy.
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Cancer of unknown primary (CUP) is a heterogeneous and
resistant disease. CUP has a poor prognosis due to the lack
of an effective standard first-line therapy. CUP usually involves
apparent metastasis in patients where primary tumors cannot
be found.1 CUP accounts for 3–5% of cancers, and its median
survival time is only 3 months. CUPs are classified as differentiated
adenocarcinomas (~60%), undifferentiated adenocarcinomas
(30%), squamous cell carcinomas (5%), neuroendocrine
tumors (~1%) and melanomas. The primary cancer site can
eventually be diagnosed in 25% of CUP patients with improved
imaging, immunohistochemistry, serum markers2 and genomic
techniques.3,4 CUP patients have been treated with various
chemotherapeutic drugs with variable success. CUP consists
of heterogeneous malignancy groups, making personalized and
precision therapy imperative. Toward this goal, we established the
patient-derived orthotopic xenograft (PDOX) nude mouse model
using the surgical orthotopic implantation (SOI) technique.4,5 Our
PDOX model has many advantages over subcutaneous-transplant
models.6 We previously reported that tumor-targeting S. typhi-
murium A1-R was effective against many types of PDOX models.7,8
The present study aimed to identify an effective therapy for a CUP
patient using a PDOX model. In this report, we investigated the
usefulness of a PDOX model for precisely identifying effective and
ineffective chemotherapy. We also compared the efficacy of S.
typhimurium A1-R with first-line chemotherapy using the CUP
PDOX model.
The present study used 4- to 6-week-old, athymic nu/nu nude
mice (AntiCancer, Inc., San Diego, CA, USA). All experimental
protocols and data were collected as previously described.4–8
The patient CUP tumor was resected in a left neck lymph node
in the Department of Surgery, University of California, Los
Angeles (UCLA). The results from positron emission tomography
(PET); bone scintigraphy; ear, nose and throat (ENT) evaluation;
and endoscopy were all negative for tumors at other sites.
Our pathological findings suggested that this tumor was
metastatic, poorly differentiated neoplasm because it was
epithelial membrane antigen-positive, periodic acid-Schiff (PAS)-
negative, and P16-positive. Because the above findings were
insufficient to diagnosis a primary tumor, this tumor was
diagnosed as CUP.
The resected fresh tumor was brought to AntiCancer, Inc. from
the UCLA Hospital, and the CUP PDOX tumor model was
established in nude mice using the SOI technique to the left
supraclavicular fossa (Fig. 1a and 3a, b). Detailed preparation,
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administration and imaging of S. typhimurium A1-R are described
in the supplementary methods. CUP PDOX models were
randomized into 5 groups when the tumor volumes reached
100mm3, which are as folllows: G1: untreated; G2: carboplatinum
(CAR); G3: paclitaxel (PAC); G4: gemcitabine (GEM); and G5: 5-
fluorouracil (5-FU). This treatment scheme for the CUP PDOX
model is shown in Fig. 1b. In addition, CUP PDOX models were
also randomized into the following 5 groups to compare S.
typhimurium A1-R with first-line chemotherapy when the tumor
volume reached 100mm3: G1: untreated control; G2: CAR; G3:
GEM; G4: 5-FU; and G5: S. typhimurium A1-R. This treatment
scheme for the CUP PDOX models is illustrated in Fig. 3b. Seven
mice were used per group. All mice were humanely killed on day
15 after initiating treatment. Detailed statistical analyses are
provided in the supplementary methods.
All animal studies were performed using an AntiCancer, Inc.
Institutional Animal Care and Use Committee (IACUC) protocol
specifically approved for this study and in accordance with the
principles and procedures outlined in the National Institute of
Health Guide for the Care and Use of Animals under Assurance
Number A3873-1. All efforts were made to minimize the number
of animals used and their suffering. For the patient study,
informed consent was obtained from the patient under UCLA
Institutional Review Board-approved protocol (IRB #10-001857) to
perform a PDOX study.
We compared the efficacy of four drugs (CAR, GEM, PAC
and 5-FU) on CUP PDOX tumor growth. Of the four drugs
tested, we found that CAR significantly suppressed tumor growth
more than the untreated group (P < 0.001) (Fig. 1c). In addition,
CAR was significantly more effective than GEM (P= 0.015) and
Fig. 1 a Surgical orthotopic implantation (SOI). A 10-mm incision was made in the left neck of the nude mice. A small CUP tumor fragment (4
mm3) was implanted in the left supraclavicular fossa (white dotted circle) of the nude mice using SOI to establish the PDOX model. Black
dotted line: left clavicle. Black arrow: left external jugular vein. Scale bar: 10 mm. b Treatment protocol. G1: untreated group; G2:
carboplatinum (CAR) (30mg/kg, i.p., weekly, 2 weeks); G3: paclitaxel (PAC) (20mg/kg, i.v., weekly, 2 weeks); G4: gemcitabine (GEM) (100 mg/kg,
i.p., weekly, 2 weeks); and G5: 5-fluorouracil (5-FU) (50mg/kg, i.p., weekly, 2 weeks). Each group consisted of 7 mice. All mice were humanely
killed on day 15. c Tumor growth. Line graphs show the relative tumor volume ratio (treatment day/day 0) throughout the treatment. CAR
suppressed tumor growth significantly compared with the untreated group (P < 0.001). CAR was significantly more effective than GEM (P=
0.015) and 5-FU (P= 0.011). PAC (P= 0.224), GEM (P= 0.492) and 5-FU (P= 0.551) showed no significant efficacy compared with the untreated
group. Error bars: ± SD. *P < 0.05, **P < 0.001. d Mouse body weight. Line graphs show the body weight ratios of each group (treatment day/
day 0). No significant differences were found between the untreated and treated groups. Error bars: ± SD
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5-FU (P= 0.011) (Fig. 1c). By contrast, PAC (P= 0.224), GEM
(P= 0.492) and 5-FU (P= 0.551) showed no significant efficacy
compared with the untreated group (Fig. 1c). The final tumor
volume ratios (day 15/day 0) were as follows: untreated group (G1)
(7.96 ± 0.78); CAR group (G2) (4.27 ± 1.1); PAC group (G3) (6.39 ±
0.72); GEM group (G4) (6.77 ± 2.1); and 5-FU group (G5) (6.84 ± 1.1)
(Fig. 1c).
We also measured body weights of the mice pre-treated and
post-treated with CAR, GEM, 5-FU, PAC, and GEM. Although the
PAC group’s relative body weight decreased slightly, no significant
difference was noted in body weight among the five groups
(Fig. 1d).
We carefully examined the histological sections of the treated
and untreated groups. Necrosis due to chemotherapy was only
found in the CAR- and PAC-treated groups (Fig. 2).
The CUP PDOX model was also used to compare the efficacy
between first-line therapy (CAR, GEM, 5-FU) and S. typhimurium
A1-R (Fig. 3a–c). We found that CAR (P < 0.001) and S. typhimurium
A1-R significantly (P < 0.001) inhibited tumor growth compared
with the untreated control. No significant (P= 0.995) difference
was observed in relative tumor volume between CAR and
S. typhimurium A1-R. In addition, the efficacies of GEM
(P= 0.057) and 5-FU (P= 0.088) were not statistically significant
compared with the untreated control. The final tumor volume
ratios (day 15/day 0) were as follows: untreated (G1) (7.90 ± 0.88);
CAR (G2) (4.56 ± 0.96); GEM (G3) (6.39 ± 1.15); 5-FU (G4) (6.50 ±
0.95); and S. typhimurium A1-R (G5) (4.36 ± 0.56) (Fig. 3d).
Mouse body weights were also measured before and after
treatment with first-line therapy and S. typhimurium A1-R.
Although the relative body weight of the S. typhimurium A1-R
group slightly decreased, it was not significant (0.94 ± 0.09).
Further, we found no significant differences in body weight
between any groups (Fig. 3e).
Distribution of S. typhimurium A1-R GFP (green fluorescent
protein) tumor-targeting was confirmed by confocal imaging with
the FV1000 (Olympus, Tokyo, Japan) (Fig. 4a, b).
We carefully examined the histological sections of the treated
and untreated groups. Moderate necrosis was observed in the CAR
group tumors (Fig. 4d). By contrast, the S. typhimurium A1-R-
treated tumors showed massive necrosis (Fig. 4g).
The present study reports the first CUP PDOX model. A
heterotopic subcutaneous xenograft CUP model was previously
reported.9 The PDOX model placed the CUP tumor at the
anatomic site of the mouse that corresponded with that of the
patient.
A few studies show limited efficacy of targeted CUP therapies.10
Several chemotherapeutic combinations have limited efficacy on
CUP.11,12 A few recent studies provided therapeutic approaches to
target CUP.13,14 Other treatment regimens were also developed
based on histologic type and gene expression.15,16 In addition, a
recent study using next-generation sequencing identified a
combinatorial strategy for CUP that targets tumor protein 53
(TP53)-associated genes, the mitogen-activated protein kinase
(MAPK) pathway, phosphoinositide 3-kinase (PI3K) signaling, and
cell-cycle-associated genes17 However, before novel therapeutic
options become clinically viable, developing personalized, preci-
sion therapy is crucial.
In the present study, we initially tested four drugs with the CUP
PDOX model: CAR, PAC, GEM, and 5-FU. These four drugs are first-
line treatments for CUP per the National Comprehensive Cancer
Fig. 2 Tumor histology. a Hematoxylin and eosin (H&E) staining of the untreated CUP PDOX tumor. b H&E staining of the CAR-treated CUP
PDOX tumor. Necrosis was observed (white arrows). c H&E staining of the PAC-treated CUP PDOX tumor. Necrosis was observed (white
arrows). d H&E staining of the GEM-treated CUP PDOX tumor. e H&E staining of the 5-FU-treated CUP PDOX tumor. Scale bar: 200 µm
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Network (NCCN) guidelines.18 Only CAR showed significant
efficacy among the four drugs. These results suggested that a
CAR-based regimen would be effective for this CUP patient and
that the patient should not be treated with PAC, GEM or 5-FU. The
present CUP PDOX study showed how the PDOX model can
precisely distinguish between different therapies.
In addition, we demonstrated that S. typhimurium A1-R has
more potential against the CUP PDOX than first-line chemother-
apy. S. typhimurium A1-R’s efficacy against CUP PDOX tumor
growth is supported by the S. typhimurium A1-R GFP’s targeting
into the tumor visualized by confocal fluorescence microscopy
and by the severe necrosis in the tumor tissue
(Fig. 4a, b).
These results have great impact since the CUP tumor grew at
the corresponding site on the nude mice as it did in the patient.
Thus, the tumor grew in the corresponding tumor microenviron-
ment (TME) in both man and mouse.
On the basis of the recent findings, S. typhimurium A1-R could
be a therapeutic option for cancers as it could inhibit or eliminate
primary and metastatic tumors by destroying tumor blood vessels
and/or elevating CD8+T-cell infiltration.8,19 In our previous
studies, we reported that tumor-targeting S. typhimurium A1-R
was highly effective in many PDOX models.7,8,19 On the basis of
the previous studies on S. typhimurium A1-R’s efficacy in various
PDOX cancer models and the present study on the CUP PDOX
model, we suggest that tumor-targeting S. typhimurium A1-R has
immense potential in curing recalcitrant cancers.20
In conclusion, our CUP PDOX model identified CAR as the only
active drug among the 4 drugs that were tested. The CUP PDOX
model has potential for precise, personalized treatment for CUP
Fig. 3 a Surgical orthotopic implantation (SOI). A 4-mm2 tumor fragment of the cancer of unknown primary (CUP) was implanted into the left
supraclavicular fossa (white circle) of the nude mice using SOI to establish the PDOX model. White dotted line: left clavicle. Scale bar: 2 mm. b
Detectable CUP PDOX tumors were established 10 days after SOI. The area surrounded by a red dotted line shows the established tumor.
Scale bar: 10 mm. c Treatment protocol. G1: untreated group; G2: carboplatinum (CAR) (30mg/kg, i.p., weekly, 2 weeks); G3: gemcitabine (GEM)
(100mg/kg, i.p., weekly, 2 weeks); G4: 5-fluorouracil (5-FU) (50mg/kg, i.p., weekly, 2 weeks); and G5: Salmonella typhimurium A1-R (S.
typhimurium A1-R) (100 CFU/body, i.v., weekly, 2 weeks). Each group consisted of 7 mice. All mice were humanely killed on day 15. d Tumor
volume ratio (Treatment day/Day 0). Line graphs show tumor volume ratios. S. typhimurium A1-R (P < 0.001) and CAR (P < 0.001) significantly
inhibited tumor growth compared with the untreated group on day 15. GEM (P= 0.057), and 5-FU (P= 0.088) did not significantly suppress
tumor growth compared with the untreated group on day 15. Error bars: ± SD. *P < 0.05, **P < 0.001. e Body weight per group. Bar graphs
show the body weight ratios of each group (pre-treatment/post-treatment). No significant differences were found between any groups. Error
bars: ± SD. L. EJV: left external jugular vein
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patients. We showed that although CAR was potentially effective as
a first-line therapy, GEM and 5-FU were not. By contrast, S.
typhimurium A1-R was significantly more effective than first-line
therapy. Collectively, we provided evidence that the CUP PDOX
could eliminate ineffective therapy and identified CAR as effec-
tive standard therapy and S. typhimurium A1-R as effective experi-
mental therapy.
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